Search results for "Scoring system"

showing 10 items of 69 documents

Evaluasi Penerapan Konsep Ekowisata di Kampung Wisata Arborek, Raja Ampat

2021

Evaluation the application of the ecotourism concept in a tourist destination is considered important in maintaining the sustainability of tourism management. Arborek tourism village is one of the best tourist villages in Raja Ampat so that the selection as a research location is considered appropriate to evaluate the application of the ecotourism concept to every tourist activity so that the existence of Arborek Tourism Village is maintained. The purpose of this study is to evaluate the application of the ecotourism concept in the Arborek tourist village. The data was taken using a closed ended questionnaire and then analyzed using the One Score One Criteria Scoring System method. The resu…

Value (ethics)GovernmentScoring systemRajabiologyEcotourismSustainabilityHospitality management studiesBusinessMarketingbiology.organism_classificationTourismJURNAL SUMBERDAYA AKUATIK INDOPASIFIK
researchProduct

Testing international dental maturation scoring system and population-specific Demirjian versions on Saudi sub-population

2013

Objectives: The purpose of this study was to test the applicability of the Demirjian method and revised versions for estimating chronological age (CA) from dental age (DA) in a sample of children. Study Design: A sample of 252 individuals of known age (4 to 14 yrs), sex (males: 125, females: 127), and ethnicity (Saudi) was collected. Each individual was aged using the original Demirjian method and revised versions, including Saudi, Kuwaiti, Belgian, and revised international curves. The differences between dental age and chronological age were analyzed using paired sample t-tests with Bonferroni corrections and multinomial regression tests at the 0.05 level of significance. Results: The res…

education.field_of_studyOral Medicine and PathologyScoring systembusiness.industryResearchPopulationeducationSample (statistics)OdontologíaDental age:CIENCIAS MÉDICAS [UNESCO]Ciencias de la saludsymbols.namesakeBonferroni correctionStatistical significancePopulation specificUNESCO::CIENCIAS MÉDICASsymbolsMedicinebusinesseducationGeneral DentistryDemographyMultinomial logistic regression
researchProduct

Investigating applicability of ratings of indicators of the CLASS Pre-K instrument

2022

When classroom observations are increasingly used for accountability and evaluation purposes, a deeper understanding of the psychometric properties of such measurement tools is needed. The present study took a unique approach to examine the psychometric properties of a commonly used classroom observation measure by testing the reliability of indicators for higher-order constructs (i.e. dimensions). We investigated the reliability of indicator ratings of the Classroom Assessment Scoring System (CLASS) Pre-K instrument in Finnish kindergarten and first grade classrooms. Twenty-one observer pairs rated 838 segments identified from the 413 lessons of 48 teachers. Variance components models were…

inter-rater reliabilityclassroom assessment scoring system pre-Khavainnointivariance components modelsopettajatopetusarviointiindicatorsindikaattoritEducationmittausmenetelmät
researchProduct

Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease.

2019

Background & Aim There is an unmet need for non-invasive biomarkers in non-alcoholic fatty liver disease (NAFLD) that can diagnose advanced disease and identify patients suitable for clinical trials. The PRO-C3 collagen neo-epitope is a putative direct marker of fibrogenesis. We assessed the performance of PRO-C3 in a large, well-characterised international NAFLD cohort and report the development and validation of 2 novel panels for the diagnosis of advanced fibrosis (F≥3) in NAFLD, including a simplified clinical score which eliminates the need for online calculators. Methods Plasma PRO-C3 levels were determined in a prospectively recruited international cohort of 449 patients with biopsy …

medicine.medical_specialtyADVANCED FIBROSISSCORING SYSTEMPROGRESSIONGastroenterologySTEATOHEPATITIS03 medical and health sciences0302 clinical medicineFibrosisInternal medicineNAFLDBiopsyInternal MedicineImmunology and AllergyMedicineSTEATOSISPRO-C3Stage (cooking)lcsh:RC799-869030304 developmental biologySteatohepatitisRISK0303 health sciencesScience & TechnologyHepatologymedicine.diagnostic_testGastroenterology & Hepatologybusiness.industryFatty liverfibrosisGastroenterologyNASHDIABETES-MELLITUSCHRONIC HEPATITISBiomarkermedicine.disease3. Good healthClinical trialCohortBIOPSYBiomarker (medicine)030211 gastroenterology & hepatologylcsh:Diseases of the digestive system. GastroenterologySteatohepatitisbusinessLife Sciences & BiomedicineResearch ArticleJHEP reports : innovation in hepatology
researchProduct

Severity of irritable bowel syndrome in patients with temporomandibular disorders: A case-control study

2019

Background To assess the risk and severity of IBS in a population of TMD patients. Material and Methods Subjects for the study group were recruited from patients attending the Dental Clinic. Health controls (HC) were recruited among patients' friends and clinic staff. All subjects filled in the RDC/TMD questionnaire and the ROME III questionnaire for the diagnosis of IBS. The IBS Severity Scoring System (IBS-SSS) was used to evaluate the severity of each case of IBS. Categorical variables were compared through the Chi square test. The risk of having abdominal pain was analysed using logistic regression. Results Twenty-two (46.8%) cases of IBS were diagnosed among TMD patients, whereas only …

medicine.medical_specialtyAbdominal painScoring systemcase-control studyPopulationTemporomandibular disordersLogistic regressionNO03 medical and health sciences0302 clinical medicineInternal medicinemedicineChi-square testTemporomandibular disorders irritable bowel syndrome facial pain case-control studyIn patienteducationGeneral DentistryIrritable bowel syndromeirritable bowel syndromeeducation.field_of_studyOral Medicine and Pathologybusiness.industryResearchCase-control studymedicine.disease:CIENCIAS MÉDICAS [UNESCO]Case-control study; Facial pain; Irritable bowel syndrome; Temporomandibular disordersstomatognathic diseasesUNESCO::CIENCIAS MÉDICAS030211 gastroenterology & hepatologymedicine.symptomfacial painbusiness030217 neurology & neurosurgery
researchProduct

Transfusion Need at Diagnosis or Its Development During the First Year of Diagnosis in Primary Myelofibrosis: Effect On Survival and Correlation with…

2009

Abstract Abstract 1909 Poster Board I-932 Background: The International Prognostic Scoring System (IPSS) for primary myelofibrosis (PMF) utilizes five independent predictors of inferior survival; of these, a hemoglobin level <10 g/dL has the highest impact on survival (Cervantes et al. Blood 2009;113:2895). In the current study, we examined the additional prognostic impact of transfusion need at diagnosis or becoming transfusion-dependent in the first year of diagnosis. These events were also correlated with JAK2 or TET2 mutational status. Methods: Patients were selected from the Mayo Clinic PMF database based on availability of bone marrow histology and IPSS-relevant information at diag…

medicine.medical_specialtyBlood transfusionbusiness.industryProportional hazards modelmedicine.medical_treatmentImmunologymyelofibrosisTransfusion HistoryCell BiologyHematologyBiochemistrySettore MED/15 - Malattie Del SangueSurgeryTransplantationLog-rank testInternational Prognostic Scoring SystemInternal medicineCohortmedicinebusinessSurvival analysisBlood
researchProduct

Guiding Principles for Chronic Total Occlusion Percutaneous Coronary Intervention. A Global Expert Consensus Document

2019

© American Heart Association, Inc.

medicine.medical_specialtyGuiding PrinciplesSCORING SYSTEMmedicine.medical_treatmentPerforation (oil well)percutaneous coronaryRevascularizationMULTICENTER CTO REGISTRYCARDIOVERTER-DEFIBRILLATOR RECIPIENTSmethodsLONG-TERM OUTCOMESPROCEDURAL OUTCOMESPhysiology (medical)treatment outcome.INTRAVASCULAR ULTRASOUNDmedicineCOMPUTED-TOMOGRAPHYIntensive care medicineinterventionHEALTH-STATUStreatmentVENTRICULAR-ARRHYTHMIASbusiness.industrypercutaneous coronary interventionStentPercutaneous coronary interventionReentryRETROGRADE APPROACHcoronary occlusionCoronary occlusionConventional PCIoutcomeCardiology and Cardiovascular Medicinebusiness
researchProduct

Efficacy, Safety, and Confirmation of the Recommended Phase 2 Dose of Ruxolitinib Plus Panobinostat in Patients with Intermediate or High-Risk Myelof…

2014

Abstract Background: Myelofibrosis (MF) is a clonal neoplastic disease resulting in bone marrow fibrosis, splenomegaly, and debilitating constitutional symptoms. The Janus kinase (JAK) pathway is often dysregulated in MF, and agents targeting this pathway have demonstrated efficacy in this disease. Ruxolitinib (RUX), a potent JAK1/JAK2 inhibitor, demonstrated superiority in spleen volume reduction, symptom improvement, and survival compared with the control arm in the phase III COMFORT-I and COMFORT-II studies. Panobinostat (PAN), a potent pan-deacetylase inhibitor (pan-DACi), inhibits JAK signaling through disruption of the interaction of JAK2 with the protein chaperone heat shock protein …

medicine.medical_specialtyRuxolitinibThrombocytosisCombination therapybusiness.industryAnemiaImmunologyCell BiologyHematologymedicine.diseaseBiochemistryDiscontinuationchemistry.chemical_compoundchemistryInternational Prognostic Scoring SystemInternal medicinePanobinostatImmunologymedicinebusinessMyelofibrosismedicine.drugBlood
researchProduct

Efficacy, Safety, and Confirmation of the Recommended Phase 2 Starting Dose of the Combination of Ruxolitinib (RUX) and Panobinostat (PAN) in Patient…

2015

Abstract BACKGROUND: MF is a myeloproliferative neoplasm characterized by bone marrow (BM) fibrosis, splenomegaly, and debilitating constitutional symptoms. RUX is a potent JAK1/JAK2 inhibitor that has demonstrated superiority in spleen volume reduction, symptom improvement, and survival in the phase 3 COMFORT studies compared with placebo and best available therapy. PAN, a potent pan-deacetylase inhibitor, inhibits JAK signaling by disrupting the interaction between JAK2 and heat shock protein 90, a protein chaperone. PAN has demonstrated reductions in splenomegaly and improvement of BM fibrosis in phase 1/2 studies. The combination of RUX and PAN demonstrated synergistic activity in precl…

medicine.medical_specialtyRuxolitinibThrombocytosisCombination therapybusiness.industryImmunologyCell BiologyHematologymedicine.diseasePlaceboBiochemistrychemistry.chemical_compoundchemistryTolerabilityInternational Prognostic Scoring SystemPanobinostatInternal medicineImmunologymedicineMyelofibrosisbusinessmedicine.drugBlood
researchProduct

A Phase 1b, Dose-Finding Study Of Ruxolitinib Plus Panobinostat In Patients With Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (PPV-MF), Or …

2013

Abstract Background Myelofibrosis (MF) is a myeloproliferative neoplasm associated with progressive, debilitating symptoms that impact patient quality of life (QoL) and reduce survival. Ruxolitinib (RUX), a potent dual JAK1/JAK2 inhibitor, demonstrated superiority in spleen volume and symptom reduction, improved health-related QoL measures, and prolonged survival compared with traditional therapies or placebo in the phase 3 COMFORT studies. Panobinostat (PAN) is a potent oral pan-deacetylase inhibitor (DACi) that inhibits JAK pathway signaling through increased acetylation of the JAK2 protein chaperone HSP90. In phase 1/2 studies in MF, PAN has shown reduction in splenomegaly and JAK2 V617F…

medicine.medical_specialtyRuxolitinibbusiness.industryeducationImmunologyCell BiologyHematologymedicine.diseasePlaceboOff-label useBiochemistryDiscontinuationInternational Prognostic Scoring SystemInternal medicineCohortImmunologymedicineMyelofibrosisbusinessAdverse effecthealth care economics and organizationsmedicine.drugBlood
researchProduct